FIGURE 2 from Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy

Bioinformatic analysis of A-to-I RNA editing in human melanoma. A and B, Negative correlation between AEI and time to death. A, AEI was determined from RNA-seq data using melanoma samples from patients prior to onset of therapy (N = 23). Y-axis is AEI for each sample, and X-axis is survival time in weeks. Spearman r was calculated, and the P value was determined by Gaussian approximation. B, As in A, except AEI was determined from RNA-seq data using melanoma samples from patients after onset of therapy (N = 23). C, Kaplan–Meier curve comparing survival time as a function of high (i.e., >50) or low (i.e., <50) pre-therapy AEI. Y-axis is percent survival, and X-axis is survival time in weeks, P = 0.02, log rank (Mantel–Cox test). D, As in C, except median survival time was compared in high and low pre-therapy AEI groups, P = 0.04; * represents P < 0.05. E and F, Correlation of ADAR mRNA levels to pre-therapy AEI and survival. E, AEI was determined from RNA-seq data using melanoma samples from patients prior to onset of therapy. ADAR mRNA levels for individual melanoma samples were determined from RNA-seq data using the DeSeq package. Spearman r was calculated, and the P value was determined by Gaussian approximation. F, As in E, except ADAR mRNA levels are compared with survival times.